DMRA
Damora Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 50 | +22 | 25.23M | $652.63M | +26 | −4 |
| Q1 2026 | 29 | +19 | 19.88M | $515.11M | +19 | n/a |
| Q4 2025 | 10 | +3 | 470.62K | $50.80M | +5 | −2 |
| Q3 2025 | 3 | +1 | 35.44K | $131,837 | +1 | n/a |
| Q2 2025 | 2 | 0 | 14.64K | $49,936 | n/a | n/a |
| Q1 2025 | 1 | 0 | 15.34K | $47,566 | n/a | n/a |
| Q4 2024 | 1 | 0 | 15.04K | $69,955 | n/a | n/a |
| Q3 2024 | 1 | +1 | 21.38K | $259,791 | +1 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 1.74K | n/a | $40.01M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 238.88K | New | $5.50M | 0.0% | New | 1 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 109.00K | New | $2.51M | 0.0% | New | 1 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 74.92K | New | $1.72M | 0.0% | New | 1 | SEC ↗ |
| 5 | The Vanguard Group ✦ (passive) | 18.25K | New | $419,863 | 0.0% | New | 1 | SEC ↗ ×3 |
| 6 | Geode Capital Management ✦ (passive) | 11.57K | New | $266,345 | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | BlackRock ✦ (passive) | 7.52K | +7420.0% | $173,035 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | UBS Group AG | 6.39K | n/a | $147,011 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Bank Of America Corp /De/ | 1.23K | n/a | $28,256 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Citigroup Inc | 1.13K | n/a | $25,932 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Fidelity (FMR) | $5.50M | 0.0% |
| Point72 Asset Management | $2.51M | 0.0% |
| Morgan Stanley | $1.72M | 0.0% |
| The Vanguard Group | $419,863 | 0.0% |
| Geode Capital Management | $266,345 | 0.0% |
Exited
| Two Sigma Investments | $75,501 | was 0.0% |
| Renaissance Technologies | $55,964 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 64 holders, 53.64M shares, $1.39B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Director, President… · 12.50K sh @ 20.23 · $252,875
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology